ArticleACS infectious diseases2019
Small Molecules Targeting the Flavivirus E Protein with Broad-Spectrum Activity and Antiviral Efficacy in Vivo.
Article in ACS infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 41 citations in OpenAlex.
- Reading between the Chains: Surface Mapping and Druggable Pockets on the Biological Assemblies of DENV-2's Protein E.ACS omega · 2026Article
- Virtual screening, molecular dynamics simulations, and antiviral evaluation of Ocimum basilicum phytoconstituents against Japanese encephalitis virus.Archives of virology · 2026Article
- Integrative proteome-wide structural analysis and high-throughput docking identify broad-spectrum antiviral scaffolds against Zika, Yellow Fever, West Nile, Saint Louis encephalitis, and Usutu viruses.Frontiers in cellular and infection microbiology · 2026Article
- Article
- A Comprehensive Review of the Development and Therapeutic Use of Antivirals in Flavivirus Infection.Viruses · 2025Review
- Repurposing Neurological Drugs Against Dengue Virus Infection.Journal of tropical medicine · 2025Review
- Envelope Protein-Targeting Zika Virus Entry Inhibitors.International journal of molecular sciences · 2024Review
- Broad-spectrum activity against mosquito-borne flaviviruses achieved by a targeted protein degradation mechanism.Nature communications · 2024Article
- Vector-Transmitted Flaviviruses: An Antiviral Molecules Overview.Microorganisms · 2023Review
- Development and evaluation of neutralizing antibodies for cross-protection against West Nile virus and Japanese encephalitis virus.Infectious medicine · 2023Article
- Structural and Synthetic Aspects of Small Ring Oxa- and Aza-Heterocyclic Ring Systems as Antiviral Activities.Viruses · 2023Review
- Virus-host Interactions in Early Japanese Encephalitis Virus Infection.Virus research · 2023Review
- A pH-dependent cluster of charges in a conserved cryptic pocket on flaviviral envelopes.eLife · 2023Article
- Article
- Development of antiviral carbon quantum dots that target the Japanese encephalitis virus envelope protein.The Journal of biological chemistry · 2022Article
- Finding a chink in the armor: Update, limitations, and challenges toward successful antivirals against flaviviruses.PLoS neglected tropical diseases · 2022Review
- Advancement in the Development of Therapeutics Against Zika Virus Infection.Frontiers in cellular and infection microbiology · 2022Review
- Small-Molecule Inhibition of Viral Fusion Glycoproteins.Annual review of virology · 2021Review
- Flavivirus: From Structure to Therapeutics Development.Life (Basel, Switzerland) · 2021Review
- Castanospermine reduces Zika virus infection-associated seizure by inhibiting both the viral load and inflammation in mouse models.Antiviral research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
Vaccines and antivirals to combat dengue, Zika, and other flavivirus pathogens present a major, unmet medical need. Vaccine development has been severely challenged by the antigenic diversity of these viruses and the propensity of non-neutralizing, cross-reactive antibodies to facilitate cellular infection and increase disease severity. As an alternative, direct-acting antivirals targeting the flavivirus envelope protein, E, have the potential to act via an analogous mode of action without the risk of antibody-dependent enhancement of infection and disease. We previously discovered that structurally diverse small molecule inhibitors of the dengue virus E protein exhibit varying levels of antiviral activity against other flaviviruses in cell culture. Here, we demonstrate that the broad-spectrum activity of several cyanohydrazones against dengue, Zika, and Japanese encephalitis viruses is due to specific inhibition of E-mediated membrane fusion during viral entry and provide proof of concept for pharmacological inhibition of E as an antiviral strategy in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.